ADC · 고형암 (전체)

53개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved53 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

ADCLimited DatastaleDongguan People's HospitalPhase 2

MRG003 (MRG003, Becotatug vedotin, MRG003 (Becotatug vedotin) and Toripalimab)

Head and Neck Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#ADC#Phase2#antibody-drug-conjugate#Dongguan
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPreclinical

ADC (Non-Investigational Antibody-Drug Conjugates, Non-Investigational Antibody-Drug Conjugates (ADC))

HER2-negative Breast Cancer; HER2 Negative Breast Carcinoma · HER2

#HER2#ADC#Preclinical#antibody-drug-conjugate#HER2-negativeBreastCancer+2
Trials 1Status Recruiting
ADCLimited DatastaleOxford BioTherapeutics LtdPhase 1

OBT076, a CD205-directed antibody-drug conjugate (OBT076, a CD205-directed antibody-drug conjugate)

Solid Tumor · CD20

#CD20#ADC#Phase1#antibody-drug-conjugate#SolidTumor+1
Trials 1Status Recruiting
ADCLimited DatastaleBioAtla, Inc.Phase 2

Ozuriftamab Vedotin (Ozuriftamab Vedotin)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Active
ADCLimited DatastaleMerckPhase 2

PEV (Pembrolizumab & Enfortumab Vedotin, Pembrolizumab & Enfortumab Vedotin (PEV))

Urothelial Carcinoma · Urothelial Carcinoma

#UrothelialCarcinoma#ADC#Phase2#antibody-drug-conjugate#Merck
Trials 1Status Recruiting
ADCLimited DatastaleMerckPhase 2

pembrolizumab (Keytruda, Pembrolizumab + Enfortumab Vedotin)

Bellini Carcinoma; Collecting Duct Carcinoma · Bellini Carcinoma

#BelliniCarcinoma#ADC#Phase2#antibody-drug-conjugate#CollectingDuctCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase I: Glembatumumab Vedotin (Phase I: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

Phase II: Glembatumumab Vedotin (Phase II: Glembatumumab Vedotin)

Squamous Cell Carcinoma of the Lung · Squamous Cell Carcinoma of the Lung

#SquamousCellCarcinomaoftheLung#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleBiying ChenPhase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor)

Recurrent or Metastatic Head and Neck Carcinoma · MET

#MET#ADC#Phase2#antibody-drug-conjugate#RecurrentorMetastaticHeadandNeck+1
Trials 1Status Recruiting
ADCLimited DatastaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab deruxtecan + FLO)

Esophagogastric Adenocarcinoma · Esophagogastric Adenocarcinoma

#EsophagogastricAdenocarcinoma#ADC#Phase2#antibody-drug-conjugate#Daiichi
Trials 1Status Recruiting
ADCLimited DatastaleBoryung Pharmaceutical Co., LtdPhase 2

Trastzumab Deruxtecan (Trastzumab Deruxtecan)

Ovarian Cancer; Ovarian Carcinoma, Recurrent · Ovarian Cancer

#OvarianCancer#ADC#Phase2#antibody-drug-conjugate#OvarianCarcinoma+2
Trials 1Status Recruiting
ADCLimited DatastaleAstellasPreclinical

pembrolizumab (Keytruda, enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma)

Advanced Upper Tract Urothelial Carcinoma · Advanced Upper Tract Urothelial Carcinom

#AdvancedUpperTractUrothelialCarc#ADC#Preclinical#antibody-drug-conjugate#Astellas
Trials 1Status Active

3 / 3 pages

← PreviousNext →